Evaluation of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI
study id #: NCT03632213
condition: Mucopolysaccharidosis IV A, Mucopolysaccharidosis VI, Mucopolysaccharidoses, MPS IV A, MPS VI, MPS - Mucopolysaccharidosis, Morquio A Syndrome, Morquio Syndrome A, Morquio Syndrome
status: Recruiting
purpose:Mucopolysaccharidoses (MPS) are multisystemic diseases with significant clinical overlap between their types, with cardiac problems being among the most commonly observed manifestations and are also among the main causes of mortality in these patients. For some of the cardiovascular manifestations, such as aortic root dilation and valve diseases, there is no effective treatment currently available. Losartan, on the other hand, has been shown to be an effective drug for dilation of the aortic root, at least in animal models. This study aims to evaluate the safety and efficacy of losartan in patients with MPS VI and other mucopolysaccharidoses.
intervention: Losartan, Placebo
results: https://clinicaltrials.gov/ct2/show/results/NCT03632213
last updated: February 26, 2022
-
Functioning Profiles of Individuals With Mucopolysaccharidosis According to the International Classification of Func...The classification of health problems of...
-
A Review of the Clinical Outcomes in Idursulfase-Treated and Untreated Filipino Patients With Mucopolysaccharidosis ...Mucopolysaccharidosis type II (MPS II; H...
-
Magnetic Resonance Imaging Findings of the Posterior Fossa in 47 Patients With Mucopolysaccharidoses: A Cross-Sectio...Mucopolysaccharidoses (MPS) is a group o...
-
Mucopolysaccharidosis Patients Have Reduced Functional CapacityMucopolysaccharidoses (MPSs) are a group...
-
Mucopolysaccharidoses (MPS) and Gene TherapyMucopolysaccharidoses (MPS) are a group ...
-
What Is Mucopolysaccharidosishttps://www.onempsvoice.com/wp-content/u...
-
Loss of Function of Mutant IDS Due to Endoplasmic Reticulum-Associated Degradation: New Therapeutic Opportunities fo...Mucopolysaccharidosis type II (MPS II) r...